Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research from University of Lyon provides new data about breast cancer
January 1st, 2009
According to recent research from Lyon, France, "Activation of the Akt/mammalian target of rapamycin (mTOR) pathway has been shown to be associated with resistance to endocrine therapy in estrogen receptor alpha (ER alpha)-positive breast cancer patients. Utmost importance is attached to strategies aimed at overcoming treatment resistance." "In this context, this work aimed to investigate whether, in breast cancer cells, the use of an mTOR inhibitor would be sufficient to reverse the resistance acquired after exposure to endocrine therapy. The ER alpha-positive human breast adenocarcinoma derived-MCF-7 cells used in this study have acquired both cross-resistance to...
Source: Women's Health Weekly (2009-01-01)
|
